Clinical trials: Tuberculosis, Latent
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Training Protocol on the Natural History of Tuberculosis
Background: Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for research and treatment studies.
- Conditions
- Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis
- Trial name
- NCT01212003
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Latent
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or…
- Trial name
- BREACH-TB (NCT06568484)
- Testing
- Bedaquiline, Isoniazid, rifapentine, Levofloxacin
- Where
- 8 sites in Mongolia, Peru and 2 more
- Volunteers
- 2,530 people
- Sponsor
- Johns Hopkins University
Tuberculosis
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB).
- Trial name
- NCT07124559
- Testing
- Rifapentine, Isoniazid, Dolutegravir
- Where
- 11 sites in Botswana, Haiti and 4 more
- Volunteers
- 144 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, TPT
Systems Analysis and Improvement Approach to Prevent TB
This randomized trial uses the evidence-based Systems Analysis and Improvement Approach (SAIA) adapted for tuberculosis (SAIA-TB) to assess the comprehensive tuberculosis (TB) care cascade across 16 clinics in rural Eastern Cape…
- Conditions
- Tuberculosis, TPT, TB - Tuberculosis
- Trial name
- SAIA-TB (NCT06314386)
- Testing
- Systems Analysis and Improvement Approach for TB (SAIA-TB)
- Where
- 16 sites in South Africa
- Volunteers
- 19,560 people
- Sponsor
- Boston College
Latent Tuberculosis, Persistent Infection
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and persistence of live mycobacteria.
- Conditions
- Latent Tuberculosis, Persistent Infection, Mycobacterium Tuberculosis
- Trial name
- TB-LIVE (NCT05621343)
- Where
- Sweden
- Volunteers
- 89 people
- Sponsor
- Region Skane
Tuberculosis, Pulmonary, Tuberculosis Infection
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as…
- Trial name
- CRUSH-TB (NCT05766267)
- Testing
- Rifabutin, Delamanid, Bedaquiline
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 288 people
- Sponsor
- Centers for Disease Control and Prevention
TB - Tuberculosis, PTLD
Intergrated Service Delivery for Lung Health Conditions
The Advancing Lung Health in Zambia project aims to improve access to integrated screening, diagnosis, and management of tuberculosis (TB) and other priority respiratory diseases at community and primary healthcare levels.
- Conditions
- TB - Tuberculosis, PTLD, COPD (Chronic Obstructive Pulmonary Disease), Computer Aided Diagnosis
- Trial name
- TB REACH W11 (NCT07816523)
- Testing
- Intergrated lung health screening, AI-Enabled Cough Sound Screening for Tuberculosis, Post-TB Lung Disease evaluation
- Where
- Zambia
- Volunteers
- 20,300 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Latent Tuberculosis Infection (LTBI), Tuberculosis (TB)
Latent Infection Freshmen Tracking for Tuberculosis
The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing…
- Trial name
- LIFT-TB (NCT07811518)
- Testing
- tuberculosis preventive treatment
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Nantong University
Autoimmune Rheumatic Diseases, Prevention
Incidence of Tuberculosis in Patients With Autoimmune Rheumatic Diseases
This is a prospective, randomized, controlled study designed to evaluate the effectiveness of annual re-screening for tuberculosis infection (TBI) (previous) in patients with autoimmune rheumatic diseases (ARDs) receiving…
- Trial name
- TB-RESCREEN (NCT07731672)
- Testing
- re-screening, No Rescreening
- Where
- Brazil
- Volunteers
- 1,660 people
- Sponsor
- University of Sao Paulo General Hospital
TB - Tuberculosis, Silicosis
KAP TB in Senior Management Officials of Companies With Increased Silica Exposure
The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight.
- Conditions
- TB - Tuberculosis, Silicosis, Occupational Exposure, Occupational Health
- Trial name
- KAP TB (NCT07749872)
- Where
- Zambia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Pediatric HIV Infection, Tuberculosis Infection
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children.
- Trial name
- NCT05069688
- Testing
- rifampicin
- Where
- Nigeria
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Pediatric HIV Infection, Latent Tuberculosis
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Tuberculosis (TB) is the leading cause of death among children living with HIV, yet insufficient data are available on the pharmacokinetics of newer TB prevention strategies in children.
- Trial name
- NCT06281834
- Testing
- Rifapentine, Dolutegravir
- Where
- Nigeria
- Volunteers
- 25 people
- Sponsor
- Brigham and Women's Hospital
Latent Tuberculosis
Tuberculosis Clinical Trials Consortium Study 35
Hypotheses: Rifapentine (given as water-dispersible monolayer and/or fixed dose combination with isoniazid) dosing in HIV-infected and uninfected children ≤ 12 years of age with latent TB infection (LTBI) or with exposure to…
- Trial name
- NCT03730181
- Testing
- Rifapentine, Isoniazid
- Where
- South Africa
- Volunteers
- 69 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis Infection, Latent, Tuberculosis Active
SCAF-TB - Saving Children and Their Families From Tuberculosis: Implementation Research to Improve TB Preventive Treatment Initiation and Completion Rates Among Contact Persons in Tajikistan and Tanzania
The SCAF-TB study aims to evaluate how the WHO-endorsed SIILTIBCY skin test can be best implemented to test close contacts for tuberculosis infection (TBI) in Tajikistan and Tanzania, either facility-based or home-based delivered…
- Conditions
- Tuberculosis Infection, Latent, Tuberculosis Active, TPT
- Trial name
- SCAF-TB (NCT07714707)
- Testing
- CY-TB Patch, Audiblehealth DX
- Where
- 2 sites in Tajikistan, Tanzania
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- KNCV Tuberculosis Foundation
Latent Tuberculosis, Staphylococcus Aureus
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus…
- Trial name
- NCT05073926
- Testing
- No intervention is part of the study protocol
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Tuberculosis, Latent Tuberculosis
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.
- Trial name
- TB-YOUTH (NCT06022146)
- Testing
- isoniazid and rifapentine, Rifampin and Isoniazid
- Where
- 66 sites in China
- Volunteers
- 3,520 people
- Sponsor
- Huashan Hospital
Tuberculosis, HIV Coinfection
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV).
- Conditions
- Tuberculosis, HIV Coinfection, Tuberculosis Infection
- Trial name
- TB_GAPS (NCT05342064)
- Testing
- patient-centered TB preventive therapy, TB preventive therapy adherence support
- Where
- 5 sites in Eswatini, Lesotho and 3 more
- Volunteers
- 6,500 people
- Sponsor
- Baylor College of Medicine
Tuberculosis Infection, Latent
Shorter and Safer Treatment Regimens for Latent TB
Our study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with shorter regimens are superior with respect to…
- Trial name
- SSTARLET (NCT06498414)
- Testing
- rifampin standard arm, rifampin double dose, levofloxacin and rifapentine
- Where
- 14 sites in Benin, Brazil and 3 more
- Volunteers
- 1,800 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
Latent Tuberculosis
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
Rationale: Shorter regimens of high dose daily rifampin may be safe, and as effective as the standard rifampin regimen when taken for 4 months to treat latent TB (LTBI).
- Trial name
- 2R2 (NCT03988933)
- Testing
- Rifampin double dose, Rifampin triple dose, Rifampin standard dose
- Where
- 9 sites in Canada, Indonesia and 1 more
- Volunteers
- 1,368 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre